Anti-SARS-CoV-2 S1 (RBD) IgG ELISA Assay

$785.00

The anti-SARS-CoV-2 S1 (RBD) IgG ELISA is a highly specific enzyme immunoassay for the detection of IgG antibodies directed against SARS-CoV-2-S1 Receptor Binding Domain (RBD) in human blood. The anti-SARS-CoV-2 ELISA is For Research Use Only.

Anti-SARS-CoV-2 S1 (RBD) IgG ELISA Assay

The Anti-SARS-CoV-2 S1 (RBD) IgG ELISA Assay is for Research Use Only and not for use in diagnostic procedures

Size: 1×96 wells
Incubation Time: 2 hours 40 minutes
Sample Type: Serum and Plasma
Sample Size: 100 µl

Assay is manufactured in Germany by Mediagnost
Controls Included


Assay Principle


The Anti-SARS-CoV-2 S1 (RBD) IgG ELISA Assay is a two-step enzyme-linked immunosorbent assay. Wells of a 96-well microtiter plate are coated with recombinant SARS-CoV-2 Spike protein S1 (RBD). After addition of human serum or plasma samples anti-S1 IgG antibodies from the sample bind to the immobilized antigen during a two hours incubation followed by several washing steps in order to remove unbound components. The bound anti-SARS-CoV-2 IgG antibodies are detected by incubation with HRP conjugated anti-human IgG for 30 minutes. After removal of nonspecific bindings a HRP substrate solution containing 3,3’,5,5’-Tetramethylbenzidine (TMB) is added resulting in the formation of a blue color. The reaction is terminated by the addition of 0.2 M H2SO4 changing the blue color into yellow signals which are measured by an absorbance microtiter plate reader at 450 nm. The extinction increases with the amount of the captured IgG antibodies directed against SARS-CoV-2-S1 (RBD) from the sample.


Related Products

Coronavirus COVID-19 IgG ELISA Assay
Coronavirus COVID-19 IgM ELISA Assay Kit

Additional Information

Assay Background


In December 2019 a novel coronavirus SARS-CoV-2 was identified in Wuhan, China and was announced as the causative agent for COVID-19 disease. The incubation period of the disease is 1-14 days. Symptoms of COVID-19 include fever, fatigue, cough, shortness of breath, muscle pain and tiredness. In some severe cases, symptoms may lead to pneumonia, severe acute respiratory distress or even succumb to the disease.

The entry process of SARS-CoV-2 to the host cell is mediated by the envelope-embedded surface-located spike glycoprotein S. The protein is cleaved by host proteases into the S1 and S2 subunits, which are responsible for receptor recognition and membrane fusion, respectively.
As target antigen of the assay the recombinant Receptor Binding Domain (RBD) of SARS-CoV-2 S1 spike protein, which binds the ACE2 receptor, is used. The use of RBD increases the specificity of the assay since the domain is identical with SARS-CoV but not with MERS-CoV for example. Antibodies directed against the RBD neutralize both virus strains SARS-CoV and SARS-CoV-2.


Manual

Product Manual